GLP-1 RA use was not associated with incident severe COVID-19 and mortality in patientshospitalized for COVID-19 in the main analysis (i.e. PS-matched), whereas in the adjustedmodel including all patients the risk associated with GLP1-RA use was 10% higher. The gene discussed is GLP1R; the disease is COVID-19.